Adherex Technologies (NASDAQ:FENC) Issues Earnings Results

Adherex Technologies (NASDAQ:FENC) announced its earnings results on Thursday. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. Adherex Technologies had a negative return on equity of 183.18% and a negative net margin of 22.62%.

Here are the key takeaways from Adherex Technologies’ conference call:

• Fennec reported Q1 2026 net product sales of $15.1 million, up about 73% year over year, marking the sixth consecutive quarter of sales growth under the current commercial leadership.
• The company said its commercial push is gaining traction after launching Project Ignite, expanding the field force to 14 new territories and 4 frontline managers and increasing target prescribers from about 1,300 to more than 5,000.
• Operational metrics improved meaningfully, including a 48% quarter-over-quarter increase in completed infusions through Fennec HEARS, conversion rates reaching the company’s 80% benchmark, and adherence running around 80%.
• Management highlighted growing clinical interest in PEDMARK beyond pediatrics, including three investigator-initiated studies and four ASCO abstracts, with potential expansion into AYA and adult patient populations and new tumor types.
• Fennec ended the quarter with $40.1 million in cash and said it generated positive cash flow in Q1, but it also expects Q2 ending cash to be lower and noted it does not anticipate receiving the German milestone payment from partner Norgine.

Adherex Technologies Trading Up 35.5%

FENC stock traded up $2.41 during midday trading on Thursday, hitting $9.18. The stock had a trading volume of 2,066,082 shares, compared to its average volume of 175,188. The firm has a market capitalization of $316.95 million, a price-to-earnings ratio of -27.54 and a beta of 0.91. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $9.92. The stock has a 50-day simple moving average of $6.86 and a 200 day simple moving average of $7.56.

Wall Street Analysts Forecast Growth

FENC has been the subject of a number of recent analyst reports. Wall Street Zen cut Adherex Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a report on Tuesday, April 21st. B. Riley Financial assumed coverage on shares of Adherex Technologies in a report on Thursday, February 12th. They set a “buy” rating and a $16.00 price target for the company. Wedbush restated an “outperform” rating and set a $13.00 price target on shares of Adherex Technologies in a report on Thursday, April 16th. Finally, Zacks Research cut shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.80.

Insider Buying and Selling

In related news, Director Rosty Raykov sold 10,946 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $6.31, for a total value of $69,069.26. Following the completion of the transaction, the director directly owned 113,856 shares of the company’s stock, valued at $718,431.36. This trade represents a 8.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by institutional investors.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.